What is Ocular Therapeutix's stock-based comp?

Ocular Therapeutix (OCUL) reported stock-based comp of $15.58M in Q1 2026.

How has Ocular Therapeutix's stock-based comp changed year-over-year?

Ocular Therapeutix's stock-based comp increased by 49.0% year-over-year, from $10.46M to $15.58M.

What is the long-term trend for Ocular Therapeutix's stock-based comp?

Over 4 years (2021 to 2025), Ocular Therapeutix's stock-based comp has grown at a 30.3% compound annual growth rate (CAGR), from $14.98M to $43.18M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ocular Therapeutix OCUL Stock-Based Comp

Stock-Based Comp at other companies

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

Bausch + LombBLCO

$34M+21.4%

HRO

HarrowHROW

$3.84M-15.8%

Tarsus Pharmaceuticals, Inc.TARS

$11.97M+72.7%

Kodiak Sciences IncKOD

$12.16M-23.5%

PBH

Prestige Consumer HealthcarePBH

$2.65M-3.1%

Segments

By segment

See full

Single Reportable$15.58M+49.0%

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's stock-based comp?: Ocular Therapeutix (OCUL) reported stock-based comp of $15.58M in Q1 2026.
How has Ocular Therapeutix's stock-based comp changed year-over-year?: Ocular Therapeutix's stock-based comp increased by 49.0% year-over-year, from $10.46M to $15.58M.
What is the long-term trend for Ocular Therapeutix's stock-based comp?: Over 4 years (2021 to 2025), Ocular Therapeutix's stock-based comp has grown at a 30.3% compound annual growth rate (CAGR), from $14.98M to $43.18M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.